Article Text

Download PDFPDF
Analysis of clinical pharmacist interventions in the COVID-19 units of a French university hospital
  1. Maxime Perez1,
  2. Morgane Masse2,
  3. Anne Deldicque1,
  4. Jean Baptiste Beuscart3,
  5. Pascal De Groote4,
  6. Jacques Desbordes5,
  7. Stéphanie Fry6,
  8. Elodie Musy1,
  9. Pascal Odou2,
  10. Francois Puisieux3,
  11. Marc Lambert7,
  12. Arnaud Scherpereel8,
  13. Bertrand Décaudin2
  1. 1 CHU Lille, Institut de Pharmacie, Lille, France
  2. 2 Univ. Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France
  3. 3 ULR 2694-METRICS: Évaluation des Technologies de Santé et des Pratiques Médicales, University Lille, CHU Lille, Lille, France
  4. 4 Service de Cardiologie, Hôpital Cardiologique, Institut Pasteur de Lille, University of Lille, Lille, France
  5. 5 Department of Anaesthesiology, CHU Lille, University of Lille, Lille, France
  6. 6 Center for Infection and Immunity of Lille, Service de Pneumologie et Immuno-Allergologie, Centre de compétence pour les Maladies Pulmonaires Rares, University of Lille, Lille, France
  7. 7 Univ. Lille, INSERM U995, CHU Lille, Département de Médecine Interne et d'Immunologie clinique, F-59000 Lille, France, Lille, France
  8. 8 Pulmonary and Thoracic Oncology, CHU Lille, Hôpital Calmette, French National Network of Clinical Expert Centres for Malignant Pleural Mesothelioma Management, University of Lille, Lille, France
  1. Correspondence to Dr Morgane Masse, Faculty of Pharmacy, University of Lille, Lille 59000, France; morgane.masse{at}


Objectives The objectives were to compare clinical pharmacist interventions between two care groups: COVID-19-positive and COVID-19-negative patients, and to identify drugs that require particular attention, especially those involved in COVID-19 management.

Methods A prospective cohort study was conducted on patients with positive and negative COVID-19 statuses admitted to Lille University Hospital over 1 month. Pharmaceutical analysis instigated interventions to rectify drug-related errors. For each pharmaceutical intervention (PI), the anatomical therapeutic chemical classification of the drug and the outcome of such an intervention were specified.

Results The study included 438 patients. Prescription analysis led to 188 PIs performed on 118 patients (64 COVID-19-positive patients and 54 COVID-19-negative patients). Most drug-related problems were incorrect dosage representing 36.7% (69/188) of all interventions: 27.9% (29/104) for the COVID-19-positive group and 47.6% (40/84) for the COVID-19-negative group. The most frequent PI in 34% (64/188) of cases was terminating a drug: 27.9% (29/104) for the COVID-19-positive group and 47.6% (40/84) for the COVID-19-negative group. The main drug classes involved were antithrombotic agents (20.7%, 39/188), antibacterials for systemic use (13.8%, 26/188) and drugs for gastric acid-related disorders (6.4%, 12/188). Study population was limited to a single centre over 1 month.

Conclusion No difference in PI was noted between the two groups. The presence of pharmacists led to a reduction in drug-related prescription problems, especially for antithrombotic and antibacterial drugs for both groups. Clinical pharmacy commitment in such a pandemic is therefore important.

  • drug-related side effects and adverse reactions
  • education
  • pharmacy
  • administration
  • intravenous
  • pharmacy service
  • hospital
  • medical errors

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information.

This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information.

View Full Text